[1]BioorganicandMedicinalChemistryLetters,2011,vol.21,p.3222-3226
[2]Patent:US2010/75916,2010,A1.Locationinpatent:Page/Pagecolumn23
[3]Patent:EP1244647,2006,B1.Locationinpatent:Page/Pagecolumn19
[1]Patent:WO2007/36713,2007,A2.Locationinpatent:Page/Pagecolumn59;60
[2]Patent:WO2007/36713,2007,A2.Locationinpatent:Page/Pagecolumn58;59
[3]Patent:EP1244647,2006,B1.Locationinpatent:Page/Pagecolumn20
[4]Patent:WO2007/36713,2007,A2.Locationinpatent:Page/Pagecolumn61
[1]Patent:EP1244647,2006,B1.Locationinpatent:Page/Pagecolumn21
[1]Patent:WO2007/36717,2007,A1.Locationinpatent:Page/Pagecolumn26;27;27-28
Title: Wedge SR, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002 Aug 15;62(16):4645-55.
Title: Hegedus C, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol. 2012 Aug 1;84(3):260-7.
Title: Takeda H, et al. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res. 2013 Feb 15;319(4):417-23.
Title: Inoue K, et al. Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice. Clin Cancer Res. 2012 Jul 15;18(14):3924-33.